Replies to post #171657 on Biotech Values

[DewDiligence]

Can you elaborate on that? T.i.a.

[DewDiligence]

PFE/BMY—CHMP approves Eliquis for VTE treatment and secondary prevention:

http://in.reuters.com/article/2014/06/27/us-europe-medicine-pfizer-bristol-myers-idINKBN0F212720140627

In this same indication, Eliquis has an FDA PDUFA date of 8/24/14 (#msg-95178866).

Competitor, Xarelto has been approved for VTE treatment and secondary prevention in the US (#msg-81103054) and EU (#msg-80711606) since late 2012 and thus has a pretty big head start in this new indication for Eliquis.

Both drugs are approved in multiple jurisdictions for AF/stroke prevention and for primary VTE prevention following orthopedic surgery. Xarelto is also approved for ACS in the EU (#msg-88290069) but not the US (#msg-97335112).

[DewDiligence]

FDA approves Eliquis for acute VTE treatment and secondary prevention:

http://finance.yahoo.com/news/u-fda-approves-eliquis-apixaban-173100563.html

The PDUFA date was 8/24/14. Eliquis is already approved by the CHMP for this indication in the EU (#msg-103796130).

[DewDiligence]

JNJ—3Q14 US Xarelto sales now at annualized rate of $1.7B, +68% YoY (despite lack of approval in ACS):

http://finance.yahoo.com/news/johnson-johnson-reports-2014-third-114500454.html

Bayer books ex-US sales of Xarelto.

[DewDiligence]

Just received a spam email asking me to join a Xarelto-injury lawsuit, LOL.

[DewDiligence]

Eliquis is now selling at a $900M annualized rate, 50% ex-US:

http://finance.yahoo.com/news/bristol-myers-squibb-reports-third-113000988.html

Eliquis sales remain less than I expected at this point in the drug’s launch, but they are no longer an afterthought.

[DewDiligence]

Eliquis now has leading NRx share in US and Japan, according to PFE’s 4Q14 CC.